Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

BCRX | Biocryst Pharmaceuticals Inc.

Index	RUT	P/E	-	EPS (ttm)	-1.29	Insider Own	1.51%	Shs Outstand	187.91M	Perf Week	0.12%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-0.63	Insider Trans	-0.83%	Shs Float	185.31M	Perf Month	4.13%
Income	-242.72M	PEG	-	EPS next Q	-0.24	Inst Own	92.52%	Short Float / Ratio	22.29% / 16.29	Perf Quarter	7.70%
Sales	306.64M	P/S	4.66	EPS this Y	17.29%	Inst Trans	-1.83%	Short Interest	41.30M	Perf Half Y	-11.30%
Book/sh	-2.05	P/B	-	EPS next Y	43.14%	ROA	-46.66%	Target Price	15.10	Perf Year	-40.64%
Cash/sh	2.18	P/C	3.47	EPS next 5Y	22.38%	ROE	-	52W Range	6.62 - 14.50	Perf YTD	-34.33%
Dividend	-	P/FCF	-	EPS past 5Y	-11.25%	ROI	-55.62%	52W High	-48.01%	Beta	1.85
Dividend %	-	Quick Ratio	5.18	Sales past 5Y	181.93%	Gross Margin	96.87%	52W Low	13.89%	ATR	0.35
Employees	531	Current Ratio	5.47	Sales Q/Q	25.88%	Oper. Margin	-36.81%	RSI (14)	57.22	Volatility	5.67% 4.31%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-25.61%	Profit Margin	-79.15%	Rel Volume	0.60	Prev Close	7.35
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 03 BMO	Payout	-	Avg Volume	2.54M	Price	7.54
Recom	1.55	SMA20	6.08%	SMA50	5.01%	SMA200	-11.69%	Volume	761,638	Change	2.57%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight	$7
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy	$5 → $4
May-24-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4.50
Nov-16-18	Resumed	Piper Jaffray	Overweight	$15
Aug-08-18	Resumed	JP Morgan	Overweight	$9

Show Previous Ratings

Sep-18-23 07:00AM	INESSS Recommends Public Reimbursement for BioCrysts ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec (GlobeNewswire) +9.93%
Sep-05-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-23 08:30AM	3 Magnificent Growth Stocks to Buy on the Dip (Motley Fool)
Aug-23-23 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-04-23 04:56PM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call Transcript (Insider Monkey) +7.34%
04:01PM	Loading…
04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-23 02:30PM	BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript (Motley Fool)
08:15AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:07AM	BioCryst: Q2 Earnings Snapshot (AP Finance)
07:00AM	BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-20-23 09:55AM	Wall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a Bet (Zacks)
07:00AM	BioCryst to Report Second Quarter 2023 Financial Results on August 3 (GlobeNewswire)
Jul-19-23 07:00AM	BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey (GlobeNewswire)
Jul-18-23 09:42AM	Investing in BioCryst Pharmaceuticals (NASDAQ:BCRX) three years ago would have delivered you a 40% gain (Simply Wall St.)
Jul-17-23 07:00AM	BioCryst to Participate in the 2023 US HAEA National Summit (GlobeNewswire)
09:43AM	Loading…
Jul-13-23 09:43AM	Meta upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
Jul-06-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-03-23 04:23AM	Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jun-06-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-23 07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
May-31-23 07:02AM	BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire)
May-22-23 07:00AM	BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile (GlobeNewswire)
May-09-23 10:21AM	BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last week (Simply Wall St.)
May-04-23 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-23 02:00PM	BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript (Motley Fool) +12.48%
01:44PM	Why BioCryst Pharmaceuticals Stock Is Soaring Today (Motley Fool)
07:13AM	BioCryst: Q1 Earnings Snapshot (AP Finance)
07:00AM	BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-27-23 10:03AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
07:00AM	BioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat) (GlobeNewswire)
10:02AM	Loading…
Apr-26-23 10:02AM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-19-23 07:00AM	BioCryst to Report First Quarter 2023 Financial Results on May 3 (GlobeNewswire)
Apr-18-23 07:00AM	BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon (GlobeNewswire) -7.06%
Apr-17-23 01:24PM	Lacklustre Performance Is Driving BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S (Simply Wall St.)
Apr-12-23 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-04-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-23 07:00AM	BioCryst Appoints Dr. Nancy Hutson as Chair of the Board (GlobeNewswire)
Mar-29-23 04:01PM	BioCryst Celebrates Bob Ingrams Contributions to the Companys Success (GlobeNewswire)
Mar-08-23 03:00PM	CADTH Recommends Reimbursement for BioCrysts ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada (GlobeNewswire)
Mar-02-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-24-23 07:00AM	BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat) (GlobeNewswire)
Feb-23-23 04:32PM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
07:39AM	BioCryst sees drug sales double but faces R&D setbacks (American City Business Journals)
Feb-22-23 03:29PM	Why Shares of BioCryst Pharmaceuticals Jumped Today (Motley Fool) +13.08%
02:31PM	Analyst Sees Attractive Entry Opportunity After BioCryst's Pipeline Setback (Benzinga)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
05:31AM	BioCryst Pharmaceuticals Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Feb-21-23 11:55AM	Why BioCryst Pharmaceuticals Stock Is Sinking Today (Motley Fool) -15.29%
11:30AM	BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript (Motley Fool)
08:35AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones (GlobeNewswire)
Feb-16-23 10:19AM	Why Earnings Season Could Be Great for BioCryst (BCRX) (Zacks)
Feb-15-23 10:00AM	Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline (Zacks)
Feb-14-23 10:00AM	BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-08-23 07:34AM	BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders have earned a 54% CAGR over the last three years (Simply Wall St.)
Feb-07-23 07:00AM	BioCryst to Report Fourth Quarter 2022 Financial Results on February 21 (GlobeNewswire)
Feb-06-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-23 07:00AM	BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting (GlobeNewswire)
Jan-26-23 07:00AM	BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema (GlobeNewswire)
Jan-23-23 07:00AM	BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe (GlobeNewswire)
Jan-12-23 06:01AM	BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Is Breakeven Near? (Simply Wall St.)
Jan-09-23 07:05AM	BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance (GlobeNewswire) -10.07%
07:00AM	BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases (GlobeNewswire)
Jan-05-23 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 09:55AM	Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know (Zacks)
07:00AM	BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 12:10PM	BioCryst (BCRX) Down as it Discontinues Developing PNH Drug (Zacks)
Dec-15-22 02:56PM	Durham pharma reshapes strategy after dropping another clinical program (American City Business Journals)
10:06AM	BioCryst Shelves Development Of Rare Blood Disorder Candidate (Benzinga)
08:52AM	BioCryst to discontinue development of drug (MarketWatch)
07:00AM	BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013 (GlobeNewswire)
Dec-05-22 04:01PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.46%
07:00AM	BioCryst to Present at JMP Securities Hematology & Oncology Summit (GlobeNewswire)
Nov-30-22 08:03AM	With 72% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing (Simply Wall St.) +5.70%
Nov-28-22 07:00AM	BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health (GlobeNewswire)
Nov-11-22 07:14PM	BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 (Investor's Business Daily)
Nov-10-22 08:00AM	BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy (GlobeNewswire) +10.39%
Nov-09-22 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-04-22 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-22 01:30PM	Biocryst Pharmaceuticals Showing Market Leadership Earns 85 RS Rating (Investor's Business Daily)
Nov-01-22 10:16PM	BioCryst Pharmaceuticals pivots strategy, will redirect $100M after discontinuing clinical program (American City Business Journals) -11.16%
03:00PM	BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript (Motley Fool)
08:15AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones (GlobeNewswire)
Oct-26-22 10:02AM	Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 10:01AM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-24-22 07:00AM	BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology (GlobeNewswire)
Oct-18-22 07:00AM	BioCryst to Report Third Quarter 2022 Financial Results on November 1 (GlobeNewswire)
Oct-10-22 02:51PM	BioCryst Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily)
Oct-04-22 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.92%
Oct-02-22 07:54AM	Got $3,000? Here Are 2 Stocks That Will Make You Richer (Motley Fool)
Sep-20-22 09:16PM	3 Biotech Stocks to Buy Now for Extraordinary Gains (InvestorPlace)
Sep-14-22 04:01PM	BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer (GlobeNewswire)
09:00AM	Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence (GlobeNewswire)
Sep-06-22 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 07:27AM	Investors might be losing patience for BioCryst Pharmaceuticals' (NASDAQ:BCRX) increasing losses, as stock sheds 6.1% over the past week (Simply Wall St.)
Aug-31-22 04:01PM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	FDA Grants Orphan Drug Designation for BioCrysts ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva (GlobeNewswire)
Aug-29-22 07:41AM	Durham drugmaker receives $7M boost from feds for flu therapy (American City Business Journals)
Aug-26-22 07:00AM	BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients (GlobeNewswire)

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SANDERS MACHELLE	Director	Jun 15	Sale	7.98	4,000	31,920	25,611	Jun 15 04:37 PM
Hutson Nancy J	Director	Jun 14	Sale	8.04	12,866	103,443	81,818	Jun 15 04:33 PM
Thackray Helen M.	Chief R&D Officer	Apr 03	Sale	8.29	7,000	58,030	207,275	Apr 05 04:33 PM
Stonehouse Jon P	President & CEO	Mar 21	Option Exercise	3.22	31,055	99,997	1,039,794	Mar 23 04:40 PM
Stonehouse Jon P	President & CEO	Feb 01	Option Exercise	5.45	100,000	545,000	1,108,739	Feb 02 05:20 PM
Stonehouse Jon P	President & CEO	Feb 01	Sale	10.38	100,000	1,038,000	1,008,739	Feb 02 05:20 PM
LEE KENNETH B JR	Director	Jan 31	Option Exercise	1.71	15,000	25,650	52,118	Feb 02 05:15 PM
Stonehouse Jon P	President & CEO	Dec 15	Sale	10.90	14,100	153,690	887,730	Dec 19 05:09 PM
Gayer Charles K	Chief Commercial Officer	Dec 15	Sale	10.90	6,100	66,490	211,610	Dec 19 04:48 PM
Doyle Anthony	Chief Financial Officer	Dec 15	Sale	10.90	5,700	62,130	163,966	Dec 19 04:55 PM
Barnes Alane P	Chief Legal Officer	Dec 15	Sale	10.88	4,175	45,424	198,770	Dec 19 04:38 PM
Thackray Helen M.	Chief R&D Officer	Dec 15	Sale	10.89	3,125	34,031	133,275	Dec 19 04:58 PM
Jones Michael L	Exec. Director, Finance - PAO	Dec 15	Sale	10.90	445	4,850	10,753	Dec 19 04:45 PM
Stonehouse Jon P	President & CEO	Dec 02	Option Exercise	1.42	82,656	117,372	984,486	Dec 02 06:33 PM
Stonehouse Jon P	President & CEO	Dec 02	Sale	12.80	82,656	1,057,997	901,830	Dec 02 06:33 PM
Stonehouse Jon P	President & CEO	Dec 01	Option Exercise	1.42	214,917	305,182	1,116,747	Dec 02 06:33 PM
Jones Michael L	Exec. Director, Finance - PAO	Dec 01	Option Exercise	1.42	8,600	12,212	19,798	Dec 02 06:36 PM
Stonehouse Jon P	President & CEO	Dec 01	Sale	13.00	214,917	2,793,921	901,830	Dec 02 06:33 PM
Jones Michael L	Exec. Director, Finance - PAO	Dec 01	Sale	13.01	8,600	111,886	11,198	Dec 02 06:36 PM
Babu Yarlagadda S	Chief Discovery Officer	Nov 14	Option Exercise	1.42	100,000	142,000	330,056	Nov 16 04:19 PM
Babu Yarlagadda S	Chief Discovery Officer	Nov 14	Sale	13.88	31,515	437,428	298,541	Nov 16 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCRX | Biocryst Pharmaceuticals Inc.

Upgrade your FINVIZ experience